Although studies in animal models of inflammatory arthritis have shown that bisphosphonates ... plus either zoledronic acid 5 mg infusion (n = 18) or placebo (n = 21), at baseline and in week ...

as assessed by American College of Rheumatology 20, 50 and 70 response rates. Safety: Infusion-associated events occur in approximately 7% of patients treated with rituximab, and serious ...

On Thursday Assemblywoman Lori D. Wilson introduced a new bill, Assembly Bill 577, aimed at protecting the rights of patients with serious illnesses such as cancer and rheumatoid arthritis. This ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.